Quarterly ResultAug 5, 2026, 04:19 PM
Context Therapeutics Q2 Net Loss $(14.56)M; Discontinues CT-95
AI Summary
Context Therapeutics reported a Q2 2026 net loss of $(14.56) million, an increase from $(8.83) million in Q2 2025, with a six-month net loss of $(23.24) million. The company announced a strategic portfolio prioritization, discontinuing internal development of CT-95 to focus on CTIM-76 and CT-202. Cash and cash equivalents decreased to $43.0 million, though management believes this is sufficient for at least 12 months. Stockholders also approved an increase in authorized common stock.
Key Highlights
- Discontinued internal development of CT-95, focusing on CTIM-76 and CT-202.
- Q2 2026 net loss increased to $(14.56) million from $(8.83) million in Q2 2025.
- Six-month net loss for 2026 was $(23.24) million, up from $(13.40) million in 2025.
- Cash and cash equivalents decreased to $43.0 million as of June 30, 2026, from $66.0 million at Dec 31, 2025.
- Research and development expenses rose to $12.53 million in Q2 2026 from $7.83 million in Q2 2025.
- Accumulated deficit reached $154.1 million as of June 30, 2026.
- Stockholders approved increasing authorized common stock from 200 million to 300 million shares.
- Existing cash is projected to fund operations for at least 12 months.
Price Impact
More from CNTX